AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
Zacks.com on MSN3h
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival GoalAstraZeneca AZN and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan ...
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...
patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial Survival results for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback